Related Experiment Videos
Rhabdomyosarcoma in children. A clinicopathologic study of 35 patients
Insights
Prognosis for rhabdomyosarcoma depends on tumor stage and pathology. Early-stage disease and specific subtypes like myxoid spindle-cell offer better survival rates, while alveolar types show no survivors.
Area of Science:
- Pediatric Oncology
- Surgical Pathology
Background:
- Rhabdomyosarcoma is a rare childhood cancer.
- Treatment outcomes vary significantly based on several factors.
Purpose of the Study:
- To analyze prognostic factors in pediatric rhabdomyosarcoma.
- To evaluate the impact of treatment modalities on survival.
Main Methods:
- Retrospective analysis of 35 rhabdomyosarcoma patients treated between 1953-1973.
- Evaluation of patient age, sex, tumor site, stage, and histopathologic type.
- Assessment of outcomes following surgery, radiation, and chemotherapy.
Main Results:
- Survival rates were 86% for Stage I, 40% for Stage II, and 0% for advanced stages.
- Myxoid spindle-cell variant showed 80% survival across all stages.
- Alveolar types had 0% survival, despite longer disease duration.
Conclusions:
- Tumor stage and specific pathologic subtypes are critical prognostic indicators for rhabdomyosarcoma.
- Histopathology, particularly the myxoid spindle-cell variant, significantly influences patient survival.
- Alveolar rhabdomyosarcoma remains a highly aggressive subtype with a poor prognosis.
Abstract:
Thirty-five patients with rhabdomyosarcoma were treated at the Children's Hospital Medical Center from 1953 to 1973. Factors important in diagnosis and prognosis included age, sex, site, stage of tumor, and specific pathologic type. Effects that surgery, radiation, and chemotherapy had on survivals were also analyzed. Survivals ranged from 2 to 20 years. The rates were 86% for Stage I disease; 40% for Stage II disease, and 0 for the more advanced lesions. A useful prognostic indicator was found in pathologic subgroupings. Survivals for the myxoid spindle-cell variant were 80% for all stages. For the partial maturation series with moderately well-differentiated rhabdomyoblasts, survival was 10% for all stages. For a combination of the above two types, survival was 40% for all stages. The alveolar types had no survivors, although these patients seemed to live longer with their disease.